Controlled-Release and Localized Targeting of Interferons
Interferon’s (α and β), produced both by recombinant DNA technology as well as purified from natural sources, have been shown to be efficacious in treating certain cancers and viral diseases. Studies with γ-interferon have more recently been undertaken, and thus definition of their clinical utility is not yet as well defined. The treatment schedules usually involve multiple injections of the Interferon (IFN) over a period of several weeks to many months. Using such treatment regimens, the dose levels of the interferons needed to obtain efficacy can result in toxic side effects. For all these reasons, methods of increasing the ease of administration as well as the therapeutic ratio of interferons are warranted.
KeywordsStratum Corneum Release Profile Varicella Zoster Virus Liposomal Formulation Hairy Cell Leukemia
Unable to display preview. Download preview PDF.
- Amkraut, A.A., and Martins, A.B. (1984). Method for administering immunopotentiator. U.S. Patent #4,484,923.Google Scholar
- Bonnern, E.M. and Spiegel, R.J. (1984). Interferon-α: current status and future promise. J. Bioi. Resp. Mod. 3: 580–598.Google Scholar
- Eppstein, D.A. (1986). Alternate delivery of interferons, In “Drug Targeting with Synthetic Systems,” NATO ASI Conference, 1985, Ed. G. Gregoriadis, Plenum Pub. Co. (in press).Google Scholar
- Eppstein, D.A. and Felgner, P.L. (1987). Applications of liposome formulations for antimicrobial/antiviral therapy, in “Liposomes as Drug Carrriers: Trends and Progress,” Ed. G. Gregoriadis, John Wiley and Sons, LTD. (in press).Google Scholar